IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down – Time to Sell?

Posted by George Bondi on Jun 9th, 2026

IDEAYA Biosciences, Inc. (NASDAQ:IDYA – Get Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $31.48, but opened at $30.34. IDEAYA Biosciences shares last traded at $30.4220, with a volume of 1,085,447 shares changing hands.

Wall Street Analyst Weigh In

Several research firms have recently commented on IDYA. Truist Financial set a $65.00 price target on shares of IDEAYA Biosciences in a report on Monday, April 13th. The Goldman Sachs Group boosted their price target on shares of IDEAYA Biosciences from $31.00 to $35.00 and gave the company a “neutral” rating in a report on Tuesday, April 14th. Citigroup restated a “market outperform” rating on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a report on Tuesday, April 21st. Finally, Wedbush restated an “outperform” rating and set a $58.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, June 2nd. Fifteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $50.69.

View Our Latest Analysis on IDEAYA Biosciences

IDEAYA Biosciences Price Performance

The stock has a market capitalization of $2.51 billion, a P/E ratio of -17.80 and a beta of -0.04. The stock’s fifty day moving average is $30.18 and its 200-day moving average is $32.62.

IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.04). The company had revenue of $6.56 million for the quarter, compared to analysts’ expectations of $5.04 million. The company’s quarterly revenue was down 39.4% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.82) EPS. On average, research analysts expect that IDEAYA Biosciences, Inc. will post -4.27 EPS for the current year.

Institutional Investors Weigh In On IDEAYA Biosciences

A number of large investors have recently bought and sold shares of the business. Farther Finance Advisors LLC boosted its holdings in IDEAYA Biosciences by 171.1% during the fourth quarter. Farther Finance Advisors LLC now owns 919 shares of the company’s stock valued at $32,000 after acquiring an additional 580 shares during the period. ANTIPODES PARTNERS Ltd grew its position in shares of IDEAYA Biosciences by 49.4% in the fourth quarter. ANTIPODES PARTNERS Ltd now owns 1,150 shares of the company’s stock valued at $40,000 after purchasing an additional 380 shares during the last quarter. Aster Capital Management DIFC Ltd acquired a new stake in shares of IDEAYA Biosciences in the third quarter valued at about $38,000. Global Retirement Partners LLC acquired a new stake in shares of IDEAYA Biosciences in the fourth quarter valued at about $61,000. Finally, Abich Financial Wealth Management LLC acquired a new stake in shares of IDEAYA Biosciences in the third quarter valued at about $58,000. 98.29% of the stock is currently owned by institutional investors.

IDEAYA Biosciences Company Profile

(Get Free Report)

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.